Drug Interactions of Cyclosporine with Methotrexate
Cyclosporine and methotrexate can be combined effectively in psoriasis and psoriatic arthritis, allowing lower doses of each drug to be used, though this combination increases immunosuppression and requires careful monitoring for additive toxicities, particularly renal dysfunction. 1
Key Pharmacokinetic Interaction
When methotrexate and cyclosporine are coadministered, methotrexate concentrations (AUCs) increase by approximately 30%, while its metabolite 7-hydroxymethotrexate decreases by approximately 80% 2. The clinical significance of this interaction remains uncertain, and cyclosporine concentrations appear unaffected 2.
Primary Safety Concerns
Increased Immunosuppression
The level of immunosuppression is significantly increased when these drugs are used in combination 1. This creates heightened risk for:
- Opportunistic infections
- Reduced vaccine efficacy
- Potential malignancy risk (particularly in patients with prior PUVA or phototherapy exposure) 2
Renal Toxicity
Cyclosporine does not appear to cause additive hepatotoxicity when combined with methotrexate 1, which is reassuring. However, renal function requires close monitoring:
- Serum creatinine should be measured every 2-3 months 1
- Glomerular filtration rate should be assessed after each year of cumulative treatment 3
- Dose reductions of cyclosporine may be necessary if renal impairment develops 4
Other Toxicities
Real-world data shows patients exposed to methotrexate/cyclosporine polypharmacy have significantly greater risks of:
- Renal events (adjusted OR: 2.58) 5
- Gastrointestinal events (OR: 1.36) 5
- Pulmonary events (OR: 1.20) 5
- Increased healthcare utilization and costs 5
Clinical Use Recommendations
When to Consider Combination Therapy
The most appropriate scenario for using both drugs is during transitional periods when switching from one therapy to another 6. This prevents disease flares while the new medication takes effect.
Combination therapy may also be considered when:
- No single treatment is sufficiently effective
- Attempting to reduce cumulative exposure to each compound by using lower doses 1
- Managing severe, recalcitrant psoriasis with psoriatic arthritis 4
Dosing Strategy
Based on successful clinical experience:
- Methotrexate: 10 mg intramuscularly once weekly 7
- Cyclosporine: 2.5-3.5 mg/kg/day in divided doses 7, 8
- Duration: Short-term treatment (mean 18.9 weeks) or long-term (mean 193.2 weeks) depending on response and tolerability 4
Monitoring Requirements
Enhanced monitoring is essential:
- Baseline: Full blood count, renal function (twice to calculate mean baseline creatinine), liver function tests 1
- Ongoing: Blood pressure at each visit, serum creatinine every 2-3 months 1
- Follow-up visits: Maximum 3-monthly intervals under consultant supervision 1
- More frequent blood monitoring to detect hepatotoxicity 6
Important Caveats
Co-therapy is not recommended routinely due to increased immunosuppressive effects 6. The British Association of Dermatologists guidelines note "additional safety concerns, in particular increased immunosuppressive effects, with combining these two drugs such that co-therapy would not be recommended routinely" 6.
However, when used appropriately in selected patients with severe disease, this combination has demonstrated:
- Good control of both skin and joint problems 4
- Ability to use lower doses than monotherapy 4
- Clinically important improvement in patients with partial responses to methotrexate alone 8
Avoid this combination in patients with: